StockData
SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc. (SLS) stock

SLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$19.15+11.68 (+156.36%)

Close on Nov 17, 2026Market cap $3.87BP/E –Yield –

SELLAS Life Sciences r&d expenses

Research and development expenses are spending on new products and technology.

SELLAS Life Sciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $20.35M, up 28.2% year over year. For fiscal 2025 it was $16.02M, down 16.1% from the year before. Over ten years it grew -3.8% a year on average. The highest annual figure on record is $27.67M in fiscal 2014.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$16.02M-16.1%
FY2024Dec 31, 2024$19.10M-20.5%
FY2023Dec 31, 2023$24.01M+18.4%
FY2022Dec 31, 2022$20.27M+29.3%
FY2021Dec 31, 2021$15.67M+68.9%
FY2020Dec 31, 2020$9.28M+27.4%
FY2019Dec 31, 2019$7.29M-16.9%
FY2018Dec 31, 2018$8.77M+44.5%
FY2017Dec 31, 2017$6.07M-46.8%
FY2016Dec 31, 2016$11.40M-51.7%
FY2015Dec 31, 2015$23.61M-14.7%
FY2014Dec 31, 2014$27.67M+35.5%
FY2013Dec 31, 2013$20.42M+39.8%
FY2012Dec 31, 2012$14.61M+279.5%
FY2011Dec 31, 2011$3.85M-51.1%
FY2010Dec 31, 2010$7.87M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$6.27M+62.0%
Q1 FY2026Mar 31, 2026$5.13M+60.0%
Q4 FY2025Dec 31, 2025$4.73M+6.6%
Q3 FY2025Sep 30, 2025$4.22M-3.3%
Q2 FY2025Jun 30, 2025$3.87M-25.4%
Q1 FY2025Mar 31, 2025$3.21M-37.3%
Q4 FY2024Dec 31, 2024$4.44M-12.9%
Q3 FY2024Sep 30, 2024$4.36M-25.0%
Q2 FY2024Jun 30, 2024$5.19M-12.4%
Q1 FY2024Mar 31, 2024$5.11M-28.8%
Q4 FY2023Dec 31, 2023$5.10M-12.8%
Q3 FY2023Sep 30, 2023$5.81M+35.8%
Q2 FY2023Jun 30, 2023$5.92M+7.1%
Q1 FY2023Mar 31, 2023$7.17M+55.6%
Q4 FY2022Dec 31, 2022$5.85M+72.3%
Q3 FY2022Sep 30, 2022$4.28M-5.7%
Q2 FY2022Jun 30, 2022$5.53M+60.0%
Q1 FY2022Mar 31, 2022$4.61M+7.6%
Q4 FY2021Dec 31, 2021$3.39M+22.4%
Q3 FY2021Sep 30, 2021$4.54M+91.8%
Q2 FY2021Jun 30, 2021$3.46M+51.6%
Q1 FY2021Mar 31, 2021$4.28M+129.8%
Q4 FY2020Dec 31, 2020$2.77M+23.4%
Q3 FY2020Sep 30, 2020$2.37M+31.6%
Q2 FY2020Jun 30, 2020$2.28M+65.1%
Q1 FY2020Mar 31, 2020$1.86M+0.3%
Q4 FY2019Dec 31, 2019$2.25M-38.5%
Q3 FY2019Sep 30, 2019$1.80M+4.6%
Q2 FY2019Jun 30, 2019$1.38M-13.3%
Q1 FY2019Mar 31, 2019$1.86M+3.0%
Q4 FY2018Dec 31, 2018$3.65M+269.5%
Q3 FY2018Sep 30, 2018$1.72M+61.0%
Q2 FY2018Jun 30, 2018$1.59M-12.9%
Q1 FY2018Mar 31, 2018$1.80M-17.4%
Q4 FY2017Dec 31, 2017$988.00K-78.6%
Q3 FY2017Sep 30, 2017$1.07M-70.5%
Q2 FY2017Jun 30, 2017$1.83M–
Q1 FY2017Mar 31, 2017$2.18M–
Q4 FY2016Dec 31, 2016$4.62M–
Q3 FY2016Sep 30, 2016$3.62M–

More SELLAS Life Sciences figures

See a number that looks wrong?